Table 1

Synergy between AN9 and various anticancer drugs in growth inhibition of human lung carcinoma and lymphoma cells

DrugIC50
−AN9+AN9CI1-a
×10−7 M
Lung carcinoma EBC-1 cells
 DXR1.02  ± 0.11-b 0.43  ± <0.10.48
 DNR2.17  ± 0.11.26  ± 0.20.52
 Cytosine arabinoside4.32  ± 0.54.15  ± 0.30.98
 Methotrexate2.61  ± 0.22.93  ± 0.31.04
 6-Mercaptopurine0.84  ± 0.10.87  ± 0.11.02
Lung carcinoma PC9 cells
 DXR1.33  ± 0.20.51  ± <0.10.47
Lung carcinoma A549 cells
 DXR1.97  ± 0.30.67  ± <0.10.50
Lymphoma BALM3 cells
 DXR0.52  ± <0.10.23  ± <0.10.44
Lymphoma SKW4 cells
 DXR0.63  ± <0.10.31  ± <0.10.48

Cells were cultured with various concentrations of antineoplastic agents in the presence or absence of 32 μM AN9 for 4 days.

    • ↵1-a Combination index at IC50. CI = 1 indicates summation (additive or zero interaction), CI < 1 synergism.

    • ↵1-b Mean ± S.D. for four determinations.